Drugs / CNV2197944
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01893125 | Aug 2013 → Jun 2014 | diabetic polyneuropathy | Convergence Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01848730 | Apr 2013 → Feb 2014 | postherpetic neuralgia | Convergence Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNV2197944 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01848730 ↗ |
| Action | Inhibit | “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL5314401 ↗ |
| Modality | Small molecule | — CHEMBL5314401 ↗ |
| Route | Oral | “repeat oral dosing of CNV2197944 75 mg tid” NCT01848730 ↗ |
| Target | CACNA1B | “Voltage-gated N-type calcium channel alpha-1B subunit blocker” CHEMBL5314401 ↗ |